

Nuclear Receptor & In Vitro Toxicology Solutions™

Cynomolgus Monkey Peroxisome Proliferator-Activated Receptor Delta (nr1c2, pparD, pparδ, pparβ)

Reporter Assay System

96-well Format Assays Product # C00121

Technical Manual

(version 7.1b)

www.indigobiosciences.com

3006 Research Drive, Suite A1, State College, PA 16801, USA

Customer Service: 814-234-1919; FAX 814-272-0152 customerserv@indigobiosciences.com

Technical Service: 814-234-1919 techserv@indigobiosciences.com



Cynomolgus Monkey PPAR& Reporter Assay System 96-well Format Assays

1. Description	
The Assay System	3
The Assay Chemistry	3
Preparation of Test Compounds	4
Considerations for Automated Dispensing	4
- Assay Scheme	4
Assay Performance	5
II. Product Components & Storage Conditions	6
III. Materials to be Supplied by the User	6
IV. Assay Protocol	
A word about Antagonist-mode assay setup	7
■ DAY 1 Assay Protocol	7
■ DAY 2 Assay Protocol	9
V. Related Products	10
VI. Limited Use Disclosures	11
APPENDIX 1: Example Scheme for Serial Dilutions	12

I. Description

The Assay System

This nuclear receptor assay utilizes proprietary non-human cells engineered to provide constitutive, high-level expression of the **Cynomolgus Monkey Peroxisome Proliferator-Activated Receptor Delta** (nr1c2), a ligand-dependent transcription factor referred to herein as **cPPARδ**.

INDIGO's Reporter Cells include the luciferase gene functionally linked to a promoter that is responsive to activated cPPAR γ . Thus, quantifying changes in luciferase expression in the treated reporter cells provides a sensitive surrogate measure of the changes in cPPAR δ activity. The principal application of this assay is in the screening of test samples to quantify any functional activity, either agonist or antagonist, that they may exert against monkey PPAR δ .

Reporter Cells are prepared using INDIGO's proprietary **CryoMite™** process. This cryopreservation method yields high cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent cells into assay plates. There is no need for cumbersome intermediate treatment steps such as spin-and-rinse of cells, viability determinations, cell titer adjustments, or the pre-incubation of cells prior to assay setup.

INDIGO Bioscience's Nuclear receptor assay kits provide all-inclusive cell-based assay systems. In addition to cPPAR δ Reporter Cells, this kit provides two optimized media for use during cell culture and in diluting the user's test samples, the reference agonist GW0742, Luciferase Detection Reagent, and a cell culture-ready assay plate.

The Assay Chemistry

INDIGO's assays capitalize on the extremely low background, high-sensitivity, and broad linear dynamic range of bio-luminescence reporter gene technology.

Reporter Cells incorporate the cDNA encoding beetle luciferase, a 62 kD protein originating from the North American firefly ($Photinus\ pyralis$). Luciferase catalyzes the mono-oxidation of D-luciferin in a Mg^{+2} -dependent reaction that consumes O_2 and ATP as co-substrates, and yields as products oxyluciferin, AMP, PP_i , CO_2 , and photon emission. Luminescence intensity of the reaction is quantified using a luminometer and is reported in terms of Relative Light Units (RLU's).

INDIGO's Assays feature a luciferase detection reagent specially formulated to provide stable light emission between 5 and 90+ minutes after initiating the luciferase reaction. Incorporating a 5-minute reaction-rest period ensures that light emission profiles attain maximal stability, thereby allowing assay plates to be processed in batch. By doing so, the signal output from all sample wells, from one plate to the next, may be directly compared within an experimental set.

Preparation of Test Compounds

Most commonly, test compounds are solvated at high concentration in DMSO, and these are stored as master stocks. Master stocks are then diluted to appropriate working concentrations immediately prior to setting up the assay. Users are advised to dilute test compounds to 2x-concentration stocks using **Compound Screening Medium (CSM)**, as described in *Step 2* of the **Assay Protocol**. This method avoids the adverse effects of introducing high concentrations of DMSO into the assay. The final concentration of total DMSO carried over into assay reactions should never exceed 0.4%.

NOTE: CSM is formulated to help stabilize hydrophobic test compounds in the aqueous environment of the assay mixture. Nonetheless, high concentrations of extremely hydrophobic test compounds diluted in CSM may lack long-term stability and/or solubility, especially if further stored at low temperatures. Hence, it is recommended that test compound dilutions are prepared in CSM immediately prior to assay setup and are considered to be 'single-use' reagents.


Considerations for Automated Dispensing

When processing a small number of assay plates, first carefully consider the dead volume requirement of your dispensing instrument before committing assay reagents to its setup. In essence, "dead volume" is the volume of reagent that is dedicated to the instrument; it will *not* be available for final dispensing into assay wells. The following Table provides information on reagent volume requirements, and available excesses.

Stock Reagent & Volume provided	Volume to be Dispensed (96-well plate)	Excess rgt. volume available for instrument dead volume
Reporter Cell Suspension 12 ml (prepared from kit components)	100 μl / well 9.6 ml / plate	~ 2.4 ml
LDR 12 ml (prepared from kit components)	100 μl / well 9.6 ml / plate	~ 2.4 ml

■ Assay Scheme ■

Figure 1. Assay workflow. *In brief*, Reporter Cells are dispensed into wells of the assay plate and then immediately dosed with the user's test compounds. Following 22 -24 hr incubation, treatment media are discarded and prepared Luciferase Detection Reagent (LDR) is added. Light emission from each assay well is quantified using a plate-reading luminometer.



Cynomologus Monkey PPARδ (nr1c2) Agonist assay




Figure 2. Agonist dose-response of the monkey PPARδ receptor.

The reference agonist GW0742 (provided) was used to analyze the dose-response metrics of the monkey PPAR δ reporter cells. Average Relative Light Units (RLU) and their respective values of Standard Deviation (SD), Coefficient of Variation (CV), and Fold-Activation were calculated for each treatment concentration (n = 4). Z' was calculated as per Zhang, *et al.* (1999)¹.

Treatment concentrations were Log_{10} transformed and data were plot *via* non-linear regression and an EC₅₀ determination was performed using GraphPad Prism software.

$$Z' = 1 - [3*(SD^{Reference} + SD^{Vehicle Bkg}) / (RLU^{Reference} - RLU^{Vehicle Bkg})]$$

¹ Zhang JH, Chung TD, Oldenburg KR. (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen.:**4**(2), 67-73.

II. Product Components & Storage Conditions

This monkey PPAR δ Assay kit contains materials to perform assays in a single 96-well assay plate.

The aliquot of Reporter Cells is provided as a single-use reagent. Once thawed, cells can NOT be refrozen or maintained in extended culture with any hope of retaining downstream assay performance. Therefore, extra volumes of these reagents should be discarded after assay setup.

Assay kits are shipped on dry ice. Upon receipt, individual kit components may be stored at the temperatures indicated on their respective labels. Alternatively, the entire kit may be further stored at -80°C.

To ensure maximal viability, "Reporter Cells" must be maintained at -80°C until immediately prior to use.

The date of product expiration is printed on the Product Qualification Insert (PQI) enclosed with each kit.

Kit Components	Amount	Storage Temp.
 Monkey PPARδ Reporter Cells 	1 x 2.0 mL	-80°C
• Cell Recovery Medium (CRM)	1 x 10.5 mL	-20°C
• Compound Screening Medium (CSM)	1 x 35 mL	-20°C
• GW0742, 1.0 mM (in DMSO) (reference agonist)	1 x 30 μL	-20°C
Detection Substrate	1 x 6.0 mL	-80°C
Detection Buffer	1 x 6.0 mL	-20°C
 96-well assay plate (white, sterile, cell-culture ready) 	1	ambient

III. Materials to be Supplied by the User

The following materials must be provided by the user, and should be made ready prior to initiating the assay procedure:

DAY 1

- dry ice bucket (*Step 3*)
- cell culture-rated laminar flow hood.
- 37°C, humidified 5% CO₂ incubator for mammalian cell culture.
- 37°C water bath.
- 70% alcohol wipes
- 8-channel electronic, repeat-dispensing pipettes & sterile tips
- disposable media basins, sterile.
- sterile multi-channel media basins (such as the Heathrow Scientific "Dual-Function Solution Basin"), *or* deep-well plates, *or* appropriate similar vessel for generating dilution series of reference compound(s) and test compound(s).
- Optional: antagonist reference compound.
- Optional: clear 96-well cell culture assay plate for viewing cells on Day 2.

DAY 2 plate-reading luminometer.

IV. Assay Protocol

Review the entire Assay Protocol before starting. Completing the assay requires an overnight incubation. *Steps 1-8* are performed on **Day 1**, requiring less than 2 hours to complete. *Steps 9-14* are performed on **Day 2** and require less than 1 hour to complete.

A word about Antagonist-mode assay setup

Receptor inhibition assays expose the Reporter Cells to a constant, sub-maximal concentration (typically between $EC_{50} - EC_{85}$) of a known agonist AND the test compound(s) to be evaluated for antagonist activity. This PPAR δ Assay kit includes a 1.0 mM stock solution of **GW0742**, a reference agonist of cPPAR δ that may be used to setup antagonist-mode assays. 4 nM GW0742 typically approximates EC_{70-80} in this assay. Hence, it presents a suitable final assay concentration of agonist to be used when screening test compounds for inhibitory activity.

We find that adding the reference agonist to the bulk suspension of Reporter Cells (*i.e.*, prior to dispensing into assay wells) is the most efficient and precise method of setting up antagonist assays, and it is the method presented in *Step 5b* of the following protocol. Note that, in *Step 6*, 100 μ l of treatment media is combined with 100 μ l of pre-dispensed [Cells + agonist]. Consequently, one must prepare the bulk suspension of cells to contain a **2x**-concentration of the reference agonist. **APPENDIX 1** provides a dilution scheme that may useful when preparing the cell suspension supplemented with the desired 2x EC₈₀ concentration (8 nM) of the challenge agonist GW0742.

DAY 1 Assay Protocol: All steps must be performed using aseptic technique.

- **1.**) Remove **Cell Recovery Medium (CRM)** and **Compound Screening Medium (CSM)** from freezer storage and thaw in a 37°C water bath.
- **2.) Prepare dilutions of treatment compounds** (first see *Note 5.3*): Prepare Test Compound treatment media for *Agonist-* or *Antagonist-mode* screens.

Total DMSO carried over into assay reactions should never exceed 0.4%.

Note that, in $Step\ 6$, 100 μ l of the prepared treatment media is added into assay wells that have been pre-dispensed with 100 μ l of Reporter Cells. Hence, to achieve the desired *final* assay concentrations one must prepare treatment media with a 2x-concentration of the test and reference material(s). Plan dilution volumes carefully; this kit provides 35 ml of CSM.

Preparing the positive control: This cPPARδ Assay kit includes a 1.0 mM stock solution of the reference agonist **GW0742**. The following 7-point treatment series, with concentrations presented in 3-fold decrements, typically provides a full dose-response: 30, 10, 3.33, 1.11, 0.370, 0.123 and 0.0411nM. **APPENDIX 1** provides an example for generating such a dilution series. Always include 'no treatment' (or 'vehicle treated') control wells.

3.) Rapid Thaw of the Reporter Cells: *First*, retrieve the tube of **CRM** from the 37°C water bath and sanitize the outside with a 70% ethanol swab.

Second, retrieve **Reporter Cells** from -80°C storage and immerse in dry ice to transport the tube to a laminar flow hood. Perform a *rapid thaw* of the frozen cells by transferring a 10 ml volume of 37°C CRM into the tube of frozen cells. Recap the tube of cells and immediately place it in a 37°C water bath for 5 - 10 minutes. The resulting volume of cell suspension will be 12 ml.

- **4.**) Retrieve the tube of cell suspension from the water bath and sanitize the outside surface of the tube with a 70% alcohol swab.
- **5.)** *a. Agonist*-mode assays. Gently invert the tube of cells several times to disperse cell aggregates and gain a homogenous cell suspension. Without delay, dispense $\underline{100 \, \mu l}$ of cell suspension into each well of the assay plate.

~ or ~

- **b.** Antagonist-mode assays. Gently invert the tube of cells several times to disperse any cell aggregates, and to gain a homogenous cell suspension. Supplement the bulk suspension of cells with the desired 2x-concentrations of reference agonist (refer to "A word about antagonist-mode assay setup", pg. 7). Dispense $\underline{100 \, \mu l}$ of cell suspension into each well of the assay plate.
 - *NOTE 5.1:* Take special care to prevent cells from settling during the dispensing period. Allowing cells to settle during the transfer process, and/or lack of precision in dispensing uniform volumes across the assay plate *will* cause well-to-well variation (= increased Standard Deviation) in the assay.
 - *NOTE 5.2:* Users sometimes wish to examine the cells using a microscope. If so, the extra volume of cell suspension provided with each kit may be dispensed (100 μ l/well) into a clear 96-well cell culture treated assay plate, followed by 100 μ l/well of CSM. Incubated overnight in identical manner to those cells contained in the white assay plate.
 - *NOTE 5.3:* For logistical reasons, some users find it more convenient to first plate the cells and then prepare their test compound dilutions. That strategy works equally well. Once plated, cells may be placed in an incubator for up to 3 hours before proceeding to *Step 6*.
 - *NOTE 5.4:* If well-to-well variation due to 'edge-effects' is a concern this problem *may* be mitigated by dispensing sterile liquid into the *inter-well* spaces of the assay plate. Simply remove 1 tip from the 8-chanel dispenser and dispense 100 μ l of sterile water into each of the seven inter-well spaces per column of wells.
- **6.)** Dispense 100 µl of 2x-concentration treatment media into appropriate assay wells.
- 7.) Transfer the assay plate into a 37°C, humidified 5% CO₂ incubator for <u>22 24 hours</u>.

 NOTE: Ensure a high-humidity (≥ 85%) environment within the cell culture incubator. This is critical to prevent the onset of deleterious "edge-effects" in the assay plate.
- **8.**) For greater convenience on Day 2, retrieve the **Detection Substrate** *and* **Detection Buffer** from freezer storage and place them in a dark refrigerator (4°C) to thaw overnight.

- **DAY 2 Assay Protocol:** Subsequent manipulations do *not* require special regard for septic technique and may be performed on a bench top.
- **9.)** 30 minutes before intending to quantify receptor activity, remove **Detection Substrate** and **Detection Buffer** from the refrigerator and place them in a low-light area so that they may equilibrate to room temperature. Once at room temperature, gently invert each tube several times to ensure homogenous solutions.
 - *NOTE:* Do NOT actively warm Detection Substrate above room temperature. If these solutions were not allowed to thaw overnight at 4°C, a room temperature water bath may be used to expedite thawing.
- **10.**) Set the plate-reader to "luminescence" mode. Set the instrument to perform a single $\underline{5}$ second "plate shake" prior to reading the first assay well. Read time may be set to 0.5 second (500 mSec) per well, *or less*.
- 11.) *Immediately before proceeding to Step 12*, transfer the entire volume of Detection Buffer into the vial of Detection Substrate, thereby generating a 12 ml volume of **Luciferase Detection Reagent (LDR)**. Mix gently to avoid foaming.
- **12.**) Following 22 24 hours of incubation discard all media contents by ejecting it into an appropriate waste container. *Gently* tap the inverted plate onto a clean absorbent paper towel to remove residual droplets. Cells will remain tightly adhered to well bottoms.
- 13.) Add $\underline{100 \,\mu l}$ of **LDR** to each well of the assay plate. Allow the assay plate to rest at room temperature for at least $\underline{5 \, \text{minutes}}$. Do not shake the assay plate during this period.
- 14.) Quantify luminescence.

V. Related Products

Product No.	Product Descriptions			
Cynomolgus Monkey PPARδ Assay Products				
C00121-32	Monkey PPARδ Reporter Assay 3x 32 assays in 8-well strips (96-well plate format)			
C00121	Monkey PPARδ Reporter Assay 1x 96-well format assay			
Dog PPARδ Assay Products				
D00121-32	Dog PPARδ Reporter Assay 3x 32 assays in 8-well strips (96-well plate format)			
D00121	Dog PPARδ Reporter Assay 1x 96-well format assay			
Rat PPAR [®] Assay Products				
R00121-32	Rat PPARδ Reporter Assay 3x 32 assays in 8-well strips (96-well plate format)			
R00121	Rat PPARδ Reporter Assay 1x 96-well format assay			
	Mouse PPARδ Assay Products			
M00121-32	Mouse PPARδ Reporter Assay 3x 32 assays in 8-well strips (96-well plate format)			
M00121	Mouse PPARδ Reporter Assay 1x 96-well format assay			
]	Human PPARδ Assay Products			
IB00121-32	Human PPARδ Reporter Assay 3x 32 assays in 8-well strips (96-well plate format)			
IB00121	Human PPAR Reporter Assay 1x 96-well format assay			
IB00122	Human PPARδ Reporter Assay 1x 384-well format assays			
Panel of Human PPAR Assays				
IB00131-32P	PANEL of Human PPARγ, PPARα and PPARδ Assays 32 assays each in 8-well strips (96-well plate format)			

LIVE Cell Multiplex (LCM) Assay			
Product No.	Product Descriptions		
LCM-01	Reagents sufficient to perform 96 Live Cell Assays in 1x96-well, or 2x48-well, or 3x32-well assay plate formats		
LCM-05	Reagent in 5x-bulk volume to perform 480 Live Cell Assays performed in 5x 96-well plates		
LCM-10	Reagent in 10x-bulk volume to perform 960 Live Cell Assays performed in 10x 96-well plates		

Please refer to INDIGO Biosciences website for updated product offerings.

www.indigobiosciences.com

VI. Limited Use Disclosures

Products commercialized by INDIGO Biosciences, Inc. are for RESEARCH PURPOSES ONLY – not for therapeutic, diagnostic, or contact use in humans or animals.

"CryoMite" is a Trademark TM of INDIGO Biosciences, Inc. (State College, PA, USA)

Product prices, availability, specifications and claims are subject to change without prior notice.

Copyright © INDIGO Biosciences, Inc. (State College, PA, USA). All Rights Reserved.

APPENDIX 1: Example scheme for the serial dilution of GW0742 reference agonist, and the setup of a monkey PPARδ dose-response assay.

